|
Hyperthyroxinemia, Familial Dysalbuminemic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Familial dysalbuminemic hyperthyroxinemia (FDH-T4) and hypertriiodothyroninemia (FDH-T3) are dominantly inherited syndromes characterized by a high concentration of thyroid hormone in the blood stream.
|
29163366 |
2017 |
|
Malignant Neoplasms
|
0.010 |
GeneticVariation
|
group |
BEFREE |
ADH(3) genotype was not associated with UAT cancer.
|
10925369 |
2000 |
|
Primary malignant neoplasm
|
0.010 |
GeneticVariation
|
group |
BEFREE |
ADH(3) genotype was not associated with UAT cancer.
|
10925369 |
2000 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
FALDH mRNA levels were 4-fold decreased in streptozotocin-treated rats, suggesting that FALDH deregulation occurs both in hyperinsulinemic insulin-resistant state and hypoinsulinemic type 1 diabetes models.
|
14638678 |
2004 |
|
Sjogren-Larsson Syndrome
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
FALDH activity (nmol min-1 (mg protein)-1) in normal controls was 8.54 +/- 1.16 (mean +/- SD; range 6.95-10.77; n = 12) and in SLS heterozygotes was 5.12 +/- 1.31 (range 3.28-6.96; n = 11), or 60 +/- 15% of mean normal activity.
|
1583866 |
1992 |
|
Malignant neoplasm of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
S-nitrosoglutathione reductase in human lung cancer.
|
21816964 |
2012 |
|
Carcinoma of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
S-nitrosoglutathione reductase in human lung cancer.
|
21816964 |
2012 |
|
Primary malignant neoplasm of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
S-nitrosoglutathione reductase in human lung cancer.
|
21816964 |
2012 |
|
Fatigue
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
GSNOR null (GSNOR<sup>-/-</sup>) tibialis anterior (TA) muscles showed normal growth and were stronger and more fatigue resistant than controls in situ.
|
27412893 |
2017 |
|
Eclampsia
|
0.010 |
Biomarker
|
disease |
BEFREE |
GSNOR inhibitors offer a potentially promising option for the management of pre-eclampsia.
|
28271419 |
2017 |
|
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
GSNOR plays an important regulatory role in smooth muscle relaxation, immune function, inflammation, neuronal development and cancer progression, among many other processes.
|
28393572 |
2017 |
|
Hyperthyroxinemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
FDH-T4 is the most common cause of euthyroid hyperthyroxinemia in Caucasian populations in which its prevalence is about 1 in 10,000 individuals, but the prevalence can be much higher in some ethnic groups.
|
29163366 |
2017 |
|
Hypogonadotropic hypogonadism
|
0.010 |
Biomarker
|
disease |
BEFREE |
S-Nitrosoglutathione Reductase (GSNOR) Deficiency Results in Secondary Hypogonadism.
|
29606625 |
2018 |
|
Encephalomyelitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
S-nitrosoglutathione reductase (GSNOR) inhibitor as an immune modulator in experimental autoimmune encephalomyelitis.
|
29694854 |
2018 |
|
Acute on chronic pancreatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
ADH III has a potential role as a marker of acute and chronic pancreatitis.
|
29715134 |
2018 |
|
Hyperhomocysteinemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
GSNOR knockout or GSNO stimulation rectified HHcy-induced inflammatory cytokine secretion and T-cell proliferation.
|
29860106 |
2018 |
|
Lung diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
GSNOR inhibition increases pulmonary GSNO and induces bronchodilation while reducing inflammation in lung diseases.
|
30340896 |
2018 |
|
Sjogren-Larsson Syndrome
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
A missense mutation in the FALDH gene identified in Sjögren-Larsson syndrome patients originating from the northern part of Sweden.
|
9254849 |
1997 |
|
Malignant neoplasm of lung
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
ADH IB expression, but not ADH III, is decreased in human lung cancer.
|
23285246 |
2012 |
|
Carcinoma of lung
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
ADH IB expression, but not ADH III, is decreased in human lung cancer.
|
23285246 |
2012 |
|
Primary malignant neoplasm of lung
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
ADH IB expression, but not ADH III, is decreased in human lung cancer.
|
23285246 |
2012 |
|
Alcoholic Intoxication, Chronic
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
ADH(2), ADH(3), and CYP(450)2E1 Pst-I and Dra-I genetic variations are not related to alcoholism or susceptibility to alcoholic liver disease in our male population.ALDH(2) locus is monomorphic.
|
15519646 |
2004 |
|
Alcoholic Liver Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
ADH(2), ADH(3), and CYP(450)2E1 Pst-I and Dra-I genetic variations are not related to alcoholism or susceptibility to alcoholic liver disease in our male population.ALDH(2) locus is monomorphic.
|
15519646 |
2004 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Adoptive transfer of GSNOR<sup>-/-</sup> T cells to ApoE<sup>-/-</sup> mice fed homocysteine (Hcy) decreased atherosclerosis, with fewer infiltrated T cells and macrophages in plaques.
|
29860106 |
2018 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Adoptive transfer of GSNOR<sup>-/-</sup> T cells to ApoE<sup>-/-</sup> mice fed homocysteine (Hcy) decreased atherosclerosis, with fewer infiltrated T cells and macrophages in plaques.
|
29860106 |
2018 |